COMMUNIQUÉS West-GlobeNewswire

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
22/02/2024
MENLO PARK, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
22/02/2024
Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life [...]
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
22/02/2024
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in [...]
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
22/02/2024
MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
Health Catalyst Reports Fourth Quarter and Year End 2023 Results
22/02/2024
SOUTH JORDAN, Utah., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today [...]
Galapagos announces full year 2023 results and outlook for 2024
22/02/2024
Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of [...]
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
22/02/2024
Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch [...]
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
22/02/2024
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth quarter and full year [...]
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
22/02/2024
- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRAS G12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRAS G12C - FMC-376 has the potential to transform patient outcomes with [...]
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
22/02/2024
VALENCIA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
22/02/2024
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will [...]
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
22/02/2024
Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: 51% week 12 mean change in Total Symptom Score (TSS), [...]
Paul Johnson to run from Los Angeles to New York City in World Record attempt benefiting veterans’ nonprofit Team Red, White & Blue (Team RWB)
22/02/2024
LOS ANGELES, Feb. 22, 2024 (GLOBE NEWSWIRE) -- On March 1, 2024, Paul Johnson is commencing a life-changing challenge: running 3,000 miles across the United States from Los Angeles, CA, to New York City, N.Y. Johnson’s [...]
BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS
22/02/2024
BRIGHT GREEN CORPORATION BREAKS NEW GROUND IN DOMESTIC PHARMACEUTICAL PRODUCTION GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) company [...]
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
22/02/2024
Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February 22, 2024 . At its meeting on February 22, 2024, Sanofi’s Board of [...]
Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Clotilde Delbos, Anne-Françoise Nesmes et John Sundy en qualité d’administrateurs indépendants
22/02/2024
Le Conseil d’administration de Sanofi propose la nomination de Clotilde Delbos, Anne-Françoise Nesmes et John Sundy en qualité d’administrateurs indépendants Paris, le 22 février 2024 . Lors de sa séance du 22 février [...]
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
22/02/2024
Topline data expected in second half of 2024 THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. 22, 2024 (GLOBE [...]
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
22/02/2024
Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signals Encouraging early results from the VAXINIA (CF33) oncolytic virus trial, including one complete [...]
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
22/02/2024
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics [...]

Pages